+

WO2003045359A3 - Combination of cimetidine and cysteine derivatives for treating cancer - Google Patents

Combination of cimetidine and cysteine derivatives for treating cancer Download PDF

Info

Publication number
WO2003045359A3
WO2003045359A3 PCT/DK2002/000792 DK0200792W WO03045359A3 WO 2003045359 A3 WO2003045359 A3 WO 2003045359A3 DK 0200792 W DK0200792 W DK 0200792W WO 03045359 A3 WO03045359 A3 WO 03045359A3
Authority
WO
WIPO (PCT)
Prior art keywords
cimetidine
combination
treating cancer
cysteine derivatives
complexes
Prior art date
Application number
PCT/DK2002/000792
Other languages
French (fr)
Other versions
WO2003045359B1 (en
WO2003045359A2 (en
Inventor
Morten Sloth Weidner
Original Assignee
Astion Oncology Aps
Morten Sloth Weidner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Oncology Aps, Morten Sloth Weidner filed Critical Astion Oncology Aps
Priority to AU2002350432A priority Critical patent/AU2002350432A1/en
Publication of WO2003045359A2 publication Critical patent/WO2003045359A2/en
Publication of WO2003045359A3 publication Critical patent/WO2003045359A3/en
Publication of WO2003045359B1 publication Critical patent/WO2003045359B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to new substances in the form of chemical complexes comprising cimetidine or a derivative thereof and a cysteine derivative and to compositions comprising said complexes or combination. The invention further relates to the therapeutic effect of such combinations in relation to treating cancer, cancer chemoprevention or the suppression of hypersensitivity and/or inflammatory reactions of a mammal.
PCT/DK2002/000792 2001-11-26 2002-11-26 Combination of cimetidine and cysteine derivatives for treating cancer WO2003045359A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002350432A AU2002350432A1 (en) 2001-11-26 2002-11-26 Combination of cimetidine and cysteine derivatives for treating cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200101761 2001-11-26
DKPA200101761 2001-11-26
DKPA200201086 2002-07-10
DKPA200201086 2002-07-10
US39534402P 2002-07-12 2002-07-12
US60/395,344 2002-07-12

Publications (3)

Publication Number Publication Date
WO2003045359A2 WO2003045359A2 (en) 2003-06-05
WO2003045359A3 true WO2003045359A3 (en) 2003-12-18
WO2003045359B1 WO2003045359B1 (en) 2004-02-19

Family

ID=27222564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000792 WO2003045359A2 (en) 2001-11-26 2002-11-26 Combination of cimetidine and cysteine derivatives for treating cancer

Country Status (2)

Country Link
AU (1) AU2002350432A1 (en)
WO (1) WO2003045359A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337638A1 (en) * 2003-08-16 2005-03-24 Kirschfeld, Kuno, Prof. Dr. Method of treating prostatitis
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
US8173809B2 (en) 2008-02-07 2012-05-08 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology
EP0645138A2 (en) * 1993-09-14 1995-03-29 Marthe Dehorne Pharmaceutical composition for maintaining and/or reestablishing a rate of blood platelet aggregation clone to the normal value
WO2001056609A1 (en) * 2000-02-03 2001-08-09 Sabine Westphal Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
WO2001074780A1 (en) * 2000-03-21 2001-10-11 Astion Development Aps Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
US20020137785A1 (en) * 2001-03-26 2002-09-26 George Kindness Inflammatory mechanism modulator composition and methods with anti-asthmatic properties

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology
EP0645138A2 (en) * 1993-09-14 1995-03-29 Marthe Dehorne Pharmaceutical composition for maintaining and/or reestablishing a rate of blood platelet aggregation clone to the normal value
WO2001056609A1 (en) * 2000-02-03 2001-08-09 Sabine Westphal Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
WO2001074780A1 (en) * 2000-03-21 2001-10-11 Astion Development Aps Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
US20020137785A1 (en) * 2001-03-26 2002-09-26 George Kindness Inflammatory mechanism modulator composition and methods with anti-asthmatic properties

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"CHEMOPREVENTION OF COLORECTAL CANCER", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 43, 1998, pages 578 - 585, XP000921044, ISSN: 0017-5749 *
AL-MUSTAFA ZAKI H ET AL: "Cimetidine enhances the hepatoprotective action of N-acetylcysteine in mice treated with toxic doses of paracetamol.", TOXICOLOGY, vol. 121, no. 3, 1997, pages 223 - 228, XP001100697, ISSN: 0300-483X *
TAKEUCHI K ET AL: "EFFECTS OF TOPICAL APPLICATION OF ACIDIFIED OMEPRAZOLE ON ACID SECRETION AND TRANSMUCOSAL POTENTIAL DIFFERENCE IN ANESTHETIZED RAT STOMACHS", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 47, no. 4, 1988, pages 397 - 408, XP008009448, ISSN: 0021-5198 *

Also Published As

Publication number Publication date
AU2002350432A1 (en) 2003-06-10
AU2002350432A8 (en) 2003-06-10
WO2003045359B1 (en) 2004-02-19
WO2003045359A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP2298748A3 (en) Triazole compounds that modulate HSP90 activity
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2007094819A8 (en) Triazole compounds that modulate hsp90 activity
CA2460939A1 (en) Substituted pyrazolyl compounds for the treatment of inflammation
EP2221052A3 (en) Compositions for modulation of inflammation
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
DE60121440D1 (en) CANCER TREATMENT COMPOSITION CONTAINING AN ANTINEOPLASTIC AGENT AND PDE4 INHIBITOR
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
HK1075617A1 (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
WO2006125539A3 (en) Combination therapy comprising diaryl ureas for treating diseases
WO2003024935A3 (en) Substituted pyrazolyl compounds for the treatment of inflammation
AU6944900A (en) Fungicidal and bactericidal compositions for plants containing compounds in the form of heavy metal chelates
WO2004071382A3 (en) Substituted heterocycles
WO2004047792A3 (en) Liposomal glucocorticoids
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
CA2461567A1 (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
WO2004098524A3 (en) Lipid platinum complexes and methods of use thereof
WO2003066597A3 (en) Guanidino compounds
HK1092693A1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
WO2007025089A3 (en) Triazole compounds and methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Effective date: 20031215

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载